News & Media

Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.

Image

Media Contact:

Jill Roman

Associate Director, External Communications,
Otsuka America Pharmaceutical, Inc.

Phone:
609-249-7262
Email:
jill.roman@otsuka-us.com

Featured News

US News

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD)

Otsuka and Lundbeck announce the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration met to discuss the supplemental New Drug Application of REXULTI® (brexpiprazole) in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD).

July 18, 2025

Read more

Press Release

Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN)

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) today presented results from a pre-specified interim analysis of the Phase 3 VISIONARY study (NCT05248646) evaluating sibeprenlimab, for the treatment of immunoglobulin A nephropathy (IgAN) in adults. Patients treated with sibeprenlimab achieved a 51.2% (P<0.0001) reduction in proteinuria (as measured by 24-hour uPCR [urine protein-to-creatinine ratio]) at nine months of treatment when compared to placebo1. The data were presented during a late-breaking clinical trials session at the European Renal Association (ERA) Congress in Vienna, Austria. The study, the largest Phase 3 IgAN trial conducted to date, also showed the safety profile of sibeprenlimab was favorable and consistent with previously reported data1. 

June 06, 2025

Read more

All news

Showing:
Global News

Press Release

Otsuka Hosts Dr. Nina Vasan, Governor Charlie Baker, and Representative Jamie Raskin at Third Annual Advancing Mental Health Policy: BetterTogether Forum

Amidst COVID-19, Mental Health Leaders, Policymakers Explore Innovations and Policy Solutions to Strengthen Access to Care for People Living with Serious Mental Illness

WASHINGTON, DC – May 12, 2021 – Otsuka America Pharmaceutical, Inc. (Otsuka), a global leader in developing solutions to meet unmet mental health needs, today hosted its third-annual Advancing Mental Health Policy: BetterTogether Forum. This live, virtual event brought together more than 300 elected officials, thought leaders and stakeholders from across the mental health community to discuss the impact of COVID-19 on people living with mental illness and policies for strengthening equitable access to behavioral health care.

May 12, 2021

Read more

US News

Sozosei Foundation Awards $100,000 to American India Foundation (AIF) COVID-19 Response Fund

The Sozosei Foundation, a charitable foundation funded by Otsuka America Pharmaceutical, Inc., awarded $100,000 to the American India Foundation (AIF) COVID-19 Response Fund. This grant is drawn from Sozosei’s Disaster Relief and Recovery Philanthropy Program in response to India’s state of emergency, as the country records the highest number of cases and virus-related deaths globally.

May 05, 2021

Read more

Press Release

Otsuka and Lundbeck Announce Decision to Continue Phase III Clinical Trial Evaluating Brexpiprazole for Treatment of Agitation in Patients with Alzheimer's-type Dementia

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announce the decision to continue the recruitment of patients in the phase III clinical trial of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type (NCT03548584). The decision to continue the trial is based on the results of an independent interim analysis, supporting to progress the trial to the planned full enrollment of 330 patients.

April 13, 2021

Read more

Discover more mental
health and caregiver
perspectives.

VALUED MINDS NEWS